A share price of Design Therapeutics Inc [DSGN] is currently trading at $9.96, up 2.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DSGN shares have gain 9.21% over the last week, with a monthly amount glided 26.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Design Therapeutics Inc [NASDAQ: DSGN] stock has seen the most recent analyst activity on December 03, 2025, when Leerink Partners upgraded its rating to a Outperform but kept the price target unchanged to $14 for it. Previously, Craig Hallum started tracking the stock with Buy rating on December 03, 2025, and set its price target to $15. On November 20, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $13 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $12 on May 07, 2024. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $6 on November 14, 2023. Wedbush downgraded its rating to Neutral for this stock on August 15, 2023, and downed its price target to $6. In a note dated August 15, 2023, SVB Securities downgraded an Market Perform rating on this stock but restated the target price of $6.
Design Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.60 and $10.31. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Design Therapeutics Inc [NASDAQ: DSGN] shares were valued at $9.96 at the most recent close of the market. An investor can expect a potential return of 45.58% based on the average DSGN price forecast.
Analyzing the DSGN fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -127.43%, Pretax Profit Margin comes in at -107.97%, and Net Profit Margin reading is -107.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.27 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.70 points at the first support level, and at 9.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.16, and for the 2nd resistance point, it is at 10.36.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Design Therapeutics Inc [NASDAQ:DSGN] is 18.71. Also, the Quick Ratio is 18.71, while the Cash Ratio stands at 2.25.
Transactions by insiders
Recent insider trading involved Logos Global Master Fund LP, Director, that happened on Nov 18 ’25 when 0.12 million shares were purchased. Director, Logos Global Master Fund LP completed a deal on Nov 14 ’25 to buy 0.62 million shares. Meanwhile, Director Logos Global Master Fund LP bought 0.41 million shares on Nov 07 ’25.
